Anti-DNA antibodies: a diagnostic and prognostic tool for systemic lupus erythematosus?

Riboldi, Piersandro; Gerosa, Maria; Moroni, Gabriella; Radice, Antonella; Allegri, F.; Sinico, A.; Tincani, Anǵela; Meroni, Pier Luigi

doi:10.1080/08916930400022616

Cited by 91 publications

(76 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our findings were somewhat different to those reported [10,15,16]. Although hypocomplementemia and SLEDAI score are commonly assumed as indicators of active lupus [17], our study is the first one that identifies them as independent risk factor for poor renal outcome. Moreover, in this study, severe proliferative (LN IV) and chronic sclerotic (LN VI) lesion were also identified as risk factors, which confirmed the necessity of renal biopsy in lupus nephritis patients.…”

Section: Discussioncontrasting

confidence: 83%

Clinicopathological and outcome analysis of adult lupus nephritis patients in China

Tang

Zhang

et al. 2015

Int Urol Nephrol

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 83%

Clinicopathological and outcome analysis of adult lupus nephritis patients in China

Tang

Zhang

et al. 2015

Int Urol Nephrol

View full text Add to dashboard Cite

show abstract

“…Most studies link lupus nephritis to the presence of nephritogenic high avidity anti-dsDNA Ab as detected by C. luciliae immunofluorescence or the Farr radioactivity assay [28][29][30] . Anti-dsDNA Ab are, however, often present long before SLE is clinically apparent and they gradually obtain their nephritogenic potential through repeated antigenic stimulation 28,31,32 .…”

Section: Discussionmentioning

confidence: 99%

The Influence of the 1997 Updated Classification Criteria for Systemic Lupus Erythematosus: Epidemiology, Disease Presentation, and Patient Management

Eilertsen¹,

Becker-Merok²,

Nossent³

2009

J Rheumatol

View full text Add to dashboard Cite

ABSTRACT. Objective. The 1997 update of the American College of Rheumatology classification criteria (ACR97) for systemic lupus erythematosus (SLE) has not been validated. We determined to what extent their introduction influenced the epidemiology and clinical characteristics of the disease in northern Norway. Methods. Annual incidence and point-prevalence rates, clinical manifestations, and outcome were determined in an inception cohort of patients with SLE in northern Norway, included between 1996 and 2006, using ACR97 criteria (97acr). These findings were compared with a cohort from the same area enrolled 1978-1995 using the 1982 revised criteria ACR82 (82acr). Results. The mean annual incidence of SLE was 3.00 for cohort 97acr (n = 58) versus 2.63 for cohort 82acr (n = 81) (p = 0.5). All patients in the 97acr cohort also fulfilled the 1982 criteria; however, significantly fewer patients presented with discoid rash [odds ratio (OR) 0.31)], arthritis (OR 0.24), renal (OR 0.28) or hematological disorder (OR 0.27), and significantly more with anti-dsDNA (OR 2.57) and antiphospholipid antibodies (OR 27.9). Initial treatment with intravenous pulse methylprednisolone (OR 9.23), azathioprine (OR 6.32), and low-dose aspirin (OR 20.9) was increased in cohort 97acr. Five-(95.2%) and 10-year survival (91.9%) rates were also improved for cohort 97acr. Conclusion. The ACR97 criteria set has construct validity compared to the ACR82 criteria set. SLE incidence remains unchanged in northern Norway, but a significant reduction of renal disease and further improvements in survival rates occurred simultaneously with increased serological surveillance with ELISA-based assays and early immunosuppressive and anticoagulant therapy.

show abstract

“…Ein typisches Beispiel ist der Test auf Antikörper gegen doppelsträngige DNA, bei der eine eindeutige Antwort nur bei 2 positiven Testergebnissen gegeben werden kann [4]. Bei der systemischen Vaskulitis besteht Konsens, dass sowohl der IIF-ANCA-Test als auch ein weiterer Test auf ANCA, der für PR3, MPO, Leukozytenelastase oder das bakterielle permeabilitätssteigernde Protein (BPI) spezifisch ist, als ANCA bezeichnet werden und zur Stützung der Diagnose einer Vaskulitis oder eines medikamentös bedingten Lupussyndroms verwendet werden kann [2,9].…”

Section: Schwierige Diagnosebereicheunclassified

Diagnostische Strategien bei rheumatischen Autoimmunerkrankungen

Wiik

2007

Z. Rheumatol.

View full text Add to dashboard Cite

In order to help the clinical rheumatologist set an early and precise diagnosis and plan a rational follow-up, a close collaboration between all parties involved in the diagnostic work-up must be established. Autoimmune serology plays a key role in achieving this goal by choosing test methods that are ideal from a clinical standpoint and by presenting results obtained in such a fashion that even less experienced clinicians can correctly use the information. Simple algorithms for test ordering and for the interpretation of laboratory findings are of great benefit in daily practice, but such tools must be mutually agreed upon by the laboratory and clinical scientists. A precise diagnosis and estimation of prognosis is instrumental for optimal decision making in the clinic, but this is too complicated to be left to chance due to the inappropriate use of information. Late or wrong decisions during follow-up lead to unnecessary suffering and far higher lifetime costs for chronic diseases such as those found in rheumatology.

show abstract

Anti-DNA antibodies: a diagnostic and prognostic tool for systemic lupus erythematosus?

Cited by 91 publications

References 11 publications

Clinicopathological and outcome analysis of adult lupus nephritis patients in China

Clinicopathological and outcome analysis of adult lupus nephritis patients in China

The Influence of the 1997 Updated Classification Criteria for Systemic Lupus Erythematosus: Epidemiology, Disease Presentation, and Patient Management

Diagnostische Strategien bei rheumatischen Autoimmunerkrankungen

Contact Info

Product

Resources

About